189 related articles for article (PubMed ID: 11103071)
1. Hepatitis C virus genotype 4 and response to combination therapy with interferon-alpha2b plus ribavirin.
Bruno S; Crosignani A; Pinzello GB
Ann Intern Med; 2000 Dec; 133(11):922-3. PubMed ID: 11103071
[No Abstract] [Full Text] [Related]
2. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.
Diago M; Hassanein T; Rodés J; Ackrill AM; Sedarati F
Ann Intern Med; 2004 Jan; 140(1):72-3. PubMed ID: 14706990
[No Abstract] [Full Text] [Related]
3. Hepatitis C: are there any options for non-responders?
Romero Gómez M
Rev Esp Enferm Dig; 2005 May; 97(5):299-305. PubMed ID: 16004521
[No Abstract] [Full Text] [Related]
4. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan.
Akhtar N; Bilal M; Rizwan M; Khan MA; Khan A
Asian Pac J Cancer Prev; 2015; 16(3):1037-40. PubMed ID: 25735327
[TBL] [Abstract][Full Text] [Related]
5. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
6. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.
Bini EJ; Mehandru S
Aliment Pharmacol Ther; 2006 Mar; 23(6):777-85. PubMed ID: 16556180
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
Poynard T; Marcellin P; Lee SS; Niederau C; Minuk GS; Ideo G; Bain V; Heathcote J; Zeuzem S; Trepo C; Albrecht J
Lancet; 1998 Oct; 352(9138):1426-32. PubMed ID: 9807989
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
Kalal C; Shukla A; Mohanka R; Vora M; Patel P; Shah S
Hepatology; 2018 May; 67(5):2049-2050. PubMed ID: 29152769
[No Abstract] [Full Text] [Related]
9. Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation.
Castedal M; Siewert-Delle A; Olausson M; Friman S
Transplant Proc; 2003 Mar; 35(2):820-1. PubMed ID: 12644153
[No Abstract] [Full Text] [Related]
10. [Genotype 1 superresponder treat for only 24 weeks].
MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
[No Abstract] [Full Text] [Related]
11. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
[TBL] [Abstract][Full Text] [Related]
12. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
Ueda Y; Takada Y; Marusawa H; Egawa H; Uemoto S; Chiba T
Transplantation; 2010 Sep; 90(6):661-5. PubMed ID: 20110853
[TBL] [Abstract][Full Text] [Related]
13. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
14. Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study.
Lee SS; Kilvert L; Liu H; Trepanier J
Dig Liver Dis; 2016 Mar; 48(3):344. PubMed ID: 26459137
[No Abstract] [Full Text] [Related]
15. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
Yu ML; Dai CY; Huang JF; Chuang WL
Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
[No Abstract] [Full Text] [Related]
16. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
17. Interferon for hepatitis C patients with psychiatric disorders.
Rifai MA; Bozorg B; Rosenstein DL
Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
[No Abstract] [Full Text] [Related]
18. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
19. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
Jensen DM; Marcellin P; Freilich B; Andreone P; Di Bisceglie A; Brandão-Mello CE; Reddy KR; Craxi A; Martin AO; Teuber G; Messinger D; Thommes JA; Tietz A
Ann Intern Med; 2009 Apr; 150(8):528-40. PubMed ID: 19380853
[TBL] [Abstract][Full Text] [Related]
20. Optimal dosage of ribavirin.
Mangia A; Andriulli A
Hepatology; 2010 Sep; 52(3):1174. PubMed ID: 20812365
[No Abstract] [Full Text] [Related]
[Next] [New Search]
